{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:13Z","timestamp":1790902453588,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00105-026-05786-z","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:10:27Z","timestamp":1789128627000},"page":"666-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impfpr\u00e4vention HPV-assoziierter Erkrankungen","Vaccine prevention of HPV-associated diseases"],"prefix":"10.1007","volume":"77","author":[{"given":"Ulrike","family":"Wieland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"5786_CR1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","volume":"69","author":"L Alemany","year":"2016","unstructured":"Alemany\u00a0L, Cubilla\u00a0A, Halec\u00a0G et\u00a0al (2016) Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol 69:953\u2013961","journal-title":"Eur Urol"},{"key":"5786_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jnci\/djad189","volume":"116","author":"L Baandrup","year":"2024","unstructured":"Baandrup\u00a0L, Maltesen\u00a0T, Dehlendorff\u00a0C et\u00a0al (2024) Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer\u2011a real-world effectiveness study. J\u00a0Natl Cancer Inst 116:283\u2013287","journal-title":"J Natl Cancer Inst"},{"key":"5786_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","volume":"22","author":"P Basu","year":"2021","unstructured":"Basu\u00a0P, Malvi\u00a0SG, Joshi\u00a0S et\u00a0al (2021) Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18\u00a0infection at 10\u00a0years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a\u00a0multicentre, prospective, cohort study. Lancet Oncol 22:1518\u20131529","journal-title":"Lancet Oncol"},{"key":"5786_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ijc.32078","volume":"145","author":"HK Bertoli","year":"2019","unstructured":"Bertoli\u00a0HK, Rasmussen\u00a0CL, Sand\u00a0FL et\u00a0al (2019) Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. Int J Cancer 145:78\u201386","journal-title":"Int J Cancer"},{"key":"5786_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2289242","volume":"19","author":"N Bhatla","year":"2023","unstructured":"Bhatla\u00a0N, Muwonge\u00a0R, Malvi\u00a0SG et\u00a0al (2023) Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10\u00a0years after receiving single or higher doses of quadrivalent HPV vaccine. Hum Vaccin Immunother 19:2289242","journal-title":"Hum Vaccin Immunother"},{"key":"5786_CR6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S1473-3099(21)00071-2","volume":"21","author":"EPF Chow","year":"2021","unstructured":"Chow\u00a0EPF, Carter\u00a0A, Vickers\u00a0T et\u00a0al (2021) Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18. The Lancet. Infectious diseases 21:1747\u20131756","journal-title":"The Lancet. Infectious diseases"},{"key":"5786_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00105-023-05282-8","volume":"75","author":"D Chromy","year":"2024","unstructured":"Chromy\u00a0D, Silling\u00a0S, Wieland\u00a0U et\u00a0al (2024) Anogenital warts-An update. Dermatologie (Heidelb) 75:30\u201339","journal-title":"Dermatologie (Heidelb)"},{"key":"5786_CR8","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/S1473-3099(25)00284-1","volume":"25","author":"B Cortes","year":"2025","unstructured":"Cortes\u00a0B, Ocampo\u00a0R, Porras\u00a0C et\u00a0al (2025) Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9\u201314 years compared with three doses of quadrivalent HPV vaccine in women aged 18\u201325 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial. The Lancet. Infectious diseases 25:1314\u20131324","journal-title":"The Lancet. Infectious diseases"},{"key":"5786_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamaoncol.2025.5511","volume":"12","author":"Y Deng","year":"2026","unstructured":"Deng\u00a0Y, Wu\u00a0S, Ask\u00a0LS et\u00a0al (2026) Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions. JAMA Oncol 12:177\u2013184","journal-title":"JAMA Oncol"},{"key":"5786_CR10","unstructured":"Ecdc (2024) Efficacy, effectiveness and safety of HPV vaccination in women with conisation: a\u00a0systematic review and meta-analyses. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Efficacy-%20effectiveness%20and%20safety%20of%20HPV%20vaccination%20in%20women%20with%20conisation%20-%20FINAL_0.pdf. Zugegriffen: 30. Aug. 2026"},{"key":"5786_CR11","unstructured":"Ecdc (2026) The State of Health of HPV vaccination programmes in the EU\/EEA. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/state-health-hpv-vaccination-programmes-eueea. Zugegriffen: 30. Aug. 2026"},{"key":"5786_CR12","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","volume":"398","author":"M Falcaro","year":"2021","unstructured":"Falcaro\u00a0M, Castanon\u00a0A, Ndlela\u00a0B et\u00a0al (2021) The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 398:2084\u20132092","journal-title":"Lancet"},{"key":"5786_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","volume":"1","author":"AR Giuliano","year":"2015","unstructured":"Giuliano\u00a0AR, Viscidi\u00a0R, Torres\u00a0BN et\u00a0al (2015) Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus research (Amsterdam, Netherlands) 1:109\u2013115","journal-title":"Papillomavirus research (Amsterdam, Netherlands)"},{"key":"5786_CR14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1097\/QAD.0000000000002928","volume":"35","author":"KCM Gosens","year":"2021","unstructured":"Gosens\u00a0KCM, Van Der Zee\u00a0RP, Van Heukelom\u00a0MLS et\u00a0al (2021) HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM. AIDS 35:1753\u20131764","journal-title":"AIDS"},{"key":"5786_CR15","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1093\/infdis\/jiaf032","volume":"231","author":"P Gray","year":"2025","unstructured":"Gray\u00a0P, Wang\u00a0J, Nordqvist Kleppe\u00a0S et\u00a0al (2025) Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence. J\u00a0Infect Dis 231:e638\u2013e649","journal-title":"J Infect Dis"},{"key":"5786_CR16","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/cncr.29992","volume":"122","author":"T Guo","year":"2016","unstructured":"Guo\u00a0T, Eisele\u00a0DW, Fakhry\u00a0C (2016) The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer 122:2313\u20132323","journal-title":"Cancer"},{"key":"5786_CR17","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio C, Pasquau J, Omar-Mohamed M et\u00a0al. (2021) Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal \u3009\/= HSILs in a\u00a0Spanish Population of HIV+ MSM Aged \u3009\u202f26 Years. Viruses\u00a013","DOI":"10.3390\/v13020144"},{"key":"5786_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","volume":"13","author":"GY Ho","year":"2004","unstructured":"Ho\u00a0GY, Studentsov\u00a0YY, Bierman\u00a0R et\u00a0al (2004) Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 13:110\u2013116","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"5786_CR19","volume":"9","author":"P Kapp","year":"2025","unstructured":"Kapp\u00a0P, Schmucker\u00a0C, Siemens\u00a0W et\u00a0al (2025) Human papillomavirus (HPV) vaccination in women with conisation. Cochrane Database Syst Rev 9:CD016121","journal-title":"Cochrane Database Syst Rev"},{"key":"5786_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103865","volume":"94","author":"P Kapp","year":"2026","unstructured":"Kapp\u00a0P, Siemens\u00a0W, Gorenflo\u00a0L et\u00a0al (2026) Effectiveness, immunogenicity and safety of human papillomavirus vaccination in non-HIV immunocompromised individuals: a\u00a0systematic review. EClinicalMedicine 94:103865","journal-title":"EClinicalMedicine"},{"key":"5786_CR21","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/djab080","volume":"113","author":"SK Kjaer","year":"2021","unstructured":"Kjaer\u00a0SK, Dehlendorff\u00a0C, Belmonte\u00a0F et\u00a0al (2021) Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J\u00a0Natl Cancer Inst 113:1329\u20131335","journal-title":"J Natl Cancer Inst"},{"key":"5786_CR22","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1056\/NEJMoa2506765","volume":"393","author":"AR Kreimer","year":"2025","unstructured":"Kreimer\u00a0AR, Porras\u00a0C, Liu\u00a0D et\u00a0al (2025) Noninferiority of One HPV Vaccine Dose to Two Doses. N Engl J Med 393:2421\u20132433","journal-title":"N Engl J Med"},{"key":"5786_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","volume":"112","author":"AR Kreimer","year":"2020","unstructured":"Kreimer\u00a0AR, Sampson\u00a0JN, Porras\u00a0C et\u00a0al (2020) Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J\u00a0Natl Cancer Inst 112:1038\u20131046","journal-title":"J Natl Cancer Inst"},{"key":"5786_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","volume":"19","author":"M Lechner","year":"2022","unstructured":"Lechner\u00a0M, Liu\u00a0J, Masterson\u00a0L et\u00a0al (2022) HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 19:306\u2013327","journal-title":"Nat Rev Clin Oncol"},{"key":"5786_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203403","volume":"13","author":"BA Leconte","year":"2018","unstructured":"Leconte\u00a0BA, Szaniszlo\u00a0P, Fennewald\u00a0SM et\u00a0al (2018) Differences in the viral genome between HPV-positive cervical and oropharyngeal cancer. PloS one 13:e0203403","journal-title":"PloS one"},{"key":"5786_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1437704","volume":"14","author":"M Lehtinen","year":"2024","unstructured":"Lehtinen\u00a0M, Gray\u00a0P, Luostarinen\u00a0T et\u00a0al (2024) Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials. Front Cell Infect Microbiol 14:1437704","journal-title":"Front Cell Infect Microbiol"},{"key":"5786_CR27","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei\u00a0J, Ploner\u00a0A, Elfstrom\u00a0KM et\u00a0al (2020) HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 383:1340\u20131348","journal-title":"N Engl J Med"},{"key":"5786_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1470-2045(23)00066-9","volume":"24","author":"Z Li","year":"2023","unstructured":"Li\u00a0Z, Liu\u00a0P, Wang\u00a0Z et\u00a0al (2023) Prevalence of human papillomavirus DNA and p16(INK4a) positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol 24:403\u2013414","journal-title":"Lancet Oncol"},{"key":"5786_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","volume":"18","author":"C Lin","year":"2018","unstructured":"Lin\u00a0C, Franceschi\u00a0S, Clifford\u00a0GM (2018) Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. The Lancet. Infectious diseases 18:198\u2013206","journal-title":"The Lancet. Infectious diseases"},{"key":"5786_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102140","volume":"78","author":"Y Lu","year":"2022","unstructured":"Lu\u00a0Y, Xie\u00a0Z, Luo\u00a0G et\u00a0al (2022) Global burden of oropharyngeal cancer attributable to human papillomavirus by anatomical subsite and geographic region. Cancer Epidemiol 78:102140","journal-title":"Cancer Epidemiol"},{"key":"5786_CR31","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2468-2667(25)00297-X","volume":"11","author":"E Meglic","year":"2026","unstructured":"Meglic\u00a0E, Ploner\u00a0A, Clements\u00a0M et\u00a0al (2026) Herd effect of human papillomavirus vaccination on incidence of high-grade cervical lesions: a population-based cohort study in Sweden. Lancet Public Health 11:e35\u2013e43","journal-title":"Lancet Public Health"},{"key":"5786_CR32","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1016\/j.vaccine.2023.07.031","volume":"41","author":"S Nygard","year":"2023","unstructured":"Nygard\u00a0S, Nygard\u00a0M, Orumaa\u00a0M et\u00a0al (2023) Quadrivalent HPV vaccine effectiveness against anogenital warts: A\u00a0registry-based study of 2,2\u00a0million individuals. Vaccine 41:5469\u20135476","journal-title":"Vaccine"},{"key":"5786_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","volume":"20","author":"TB Olesen","year":"2019","unstructured":"Olesen\u00a0TB, Sand\u00a0FL, Rasmussen\u00a0CL et\u00a0al (2019) Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a\u00a0systematic review and meta-analysis. Lancet Oncol 20:145\u2013158","journal-title":"Lancet Oncol"},{"key":"5786_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","volume":"2024","author":"C Porras","year":"2024","unstructured":"Porras\u00a0C, Romero\u00a0B, Kemp\u00a0T et\u00a0al (2024) HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. J\u00a0Natl Cancer Inst Monogr 2024:329\u2013336","journal-title":"J Natl Cancer Inst Monogr"},{"key":"5786_CR35","doi-asserted-by":"crossref","unstructured":"Restrepo J, Herrera T, Samakoses R et\u00a0al. (2023) Ten-Year Follow-up of 9\u2011Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics 152","DOI":"10.1542\/peds.2022-060993"},{"key":"5786_CR36","first-page":"25","volume":"4","author":"Robert-Koch-Institut","year":"2026","unstructured":"Robert-Koch-Institut (2026) Empfehlungen der St\u00e4ndigen Impfkommission beim Robert Koch-Institut 2026. Epidemiologisches Bulletin 4:25\u201326","journal-title":"Epidemiologisches Bulletin"},{"key":"5786_CR37","first-page":"3","volume":"23","author":"Robert-Koch-Institut","year":"2026","unstructured":"Robert-Koch-Institut (2026) HPV-Impfkommunikation \u2013 Erkenntnisse aus InveSt HPV. Epidemiologisches Bulletin 23:3\u20139","journal-title":"Epidemiologisches Bulletin"},{"key":"5786_CR38","unstructured":"Robert-Koch-Institut (2025) Impfquoten in Deutschland. Epidemiologisches Bulletin\u00a050"},{"key":"5786_CR39","unstructured":"Robert-Koch-Institut (2025) STIKO: Quadrivalente Meningokokken- Impfung f\u00fcr Kleinkinder sowie \u00e4ltere Kinder, Jugendliche und junge Erwachsene. Epidemiologisches Bulletin\u00a044"},{"key":"5786_CR40","unstructured":"Robert-Koch-Institut (2026) VacMap - Dashboard zum Impfgeschehen in Deutschland. https:\/\/public.data.rki.de\/t\/public\/views\/VacMap\/StartdashboardNavigation?%3Aembed=y&%3Atabs=n. Zugegriffen: 30. Aug. 2026"},{"key":"5786_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(26)00918-9","volume":"408","author":"P Sasieni","year":"2026","unstructured":"Sasieni\u00a0P, Falcaro\u00a0M (2026) Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data. Lancet 408:162\u2013168","journal-title":"Lancet"},{"key":"5786_CR42","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","volume":"36","author":"J Schiller","year":"2018","unstructured":"Schiller\u00a0J, Lowy\u00a0D (2018) Explanations for the high potency of HPV prophylactic vaccines. Vaccine 36:4768\u20134773","journal-title":"Vaccine"},{"key":"5786_CR43","doi-asserted-by":"crossref","unstructured":"Schiller JT, Kines RC, Day PM et\u00a0al. (2026) Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines. The Lancet. Microbe:101401","DOI":"10.1016\/j.lanmic.2026.101401"},{"key":"5786_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/1471-0528.13070","volume":"122","author":"T Schwarz","year":"2015","unstructured":"Schwarz\u00a0T, Spaczynski\u00a0M, Kaufmann\u00a0A et\u00a0al (2015) Persistence of immune responses to the HPV-16\/18 AS04-adjuvanted vaccine in women aged 15\u201355 years and first-time modelling of antibody responses in mature women: results from an open-label 6\u2011year follow-up study. BJOG 122:107\u2013118","journal-title":"BJOG"},{"key":"5786_CR45","first-page":"483","volume":"122","author":"FA Stuebs","year":"2025","unstructured":"Stuebs\u00a0FA, Beckmann\u00a0MW, Poschke\u00a0P et\u00a0al (2025) The Epidemiology of Cervical Cancer in Germany: A\u00a0Registry-Based Analysis of Incidence, Survival, and Tumor Characteristics (2003-2021). Dtsch Arztebl Int 122:483\u2013488","journal-title":"Dtsch Arztebl Int"},{"key":"5786_CR46","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00103-025-04029-1","volume":"68","author":"A Takla","year":"2025","unstructured":"Takla\u00a0A, Schmid-Kupke\u00a0N, Wichmann\u00a0O (2025) Potential and limitations of school vaccination programs to increase HPV vaccination rates in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 68:416\u2013425","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"5786_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei\u00a0F, Georges\u00a0D, Man\u00a0I et\u00a0al (2024) Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet 404:435\u2013444","journal-title":"Lancet"},{"key":"5786_CR48","unstructured":"Who (2020) Cervical Cancer Elimination Initiative. https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative. Zugegriffen: 31. Aug. 2026"},{"key":"5786_CR49","unstructured":"Who (2022) One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer. Zugegriffen: 30. Aug. 2026"},{"key":"5786_CR50","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/cid\/ciy274","volume":"67","author":"TJ Wilkin","year":"2018","unstructured":"Wilkin\u00a0TJ, Chen\u00a0H, Cespedes\u00a0MS et\u00a0al (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339\u20131346","journal-title":"Clin Infect Dis"},{"key":"5786_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-087326","volume":"392","author":"S Wu","year":"2026","unstructured":"Wu\u00a0S, Deng\u00a0Y, Lepp\u00a0T et\u00a0al (2026) Extended follow-up of invasive cervical cancer risk after quadrivalent HPV vaccination: nationwide, register based study. BMJ 392:e087326","journal-title":"BMJ"},{"key":"5786_CR52","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ijc.70432","volume":"159","author":"L Yaksich","year":"2026","unstructured":"Yaksich\u00a0L, Hartel\u00a0G, Panizza\u00a0BJ et\u00a0al (2026) Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time. Int J Cancer 159:750\u2013756","journal-title":"Int J Cancer"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05786-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:09Z","timestamp":1790899449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05786-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5786"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05786-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"4 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Kreuter hat Referentengehalt f\u00fcr Vortr\u00e4ge von Merck Sharp & Dohme, Boehringer Ingelheim, Bristol Myers Squibb und UCB Pharma erhalten und an Advisory Boards von Boehringer Ingelheim, Merck Sharp & Dohme, Sanofi, Johnson\u00a0& Johnson, Fresenius und AbbVie teilgenommen. U.\u00a0Wieland gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}